



Could an Unrelated Live Attenuated Vaccine Serve as a Preventive Measure To Dampen Septic Inflammation Associated with COVID-19 Infection?

 Paul L. Fidel, Jr.,^a Mairi C. Noverr^b

^aDepartment of Oral and Craniofacial Biology, Louisiana State University Health—School of Dentistry, New Orleans, Louisiana, USA

^bDepartment of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, Louisiana, USA

ABSTRACT We propose the concept that administration of an unrelated live attenuated vaccine, such as MMR (measles, mumps, rubella), could serve as a preventive measure against the worst sequelae of coronavirus disease 2019 (COVID-19). There is mounting evidence that live attenuated vaccines provide nonspecific protection against lethal infections unrelated to the target pathogen of the vaccine by inducing “trained” nonspecific innate immune cells for improved host responses against subsequent infections. Mortality in COVID-19 cases is strongly associated with progressive lung inflammation and eventual sepsis. Vaccination with MMR in immunocompetent individuals has no contraindications and may be especially effective for health care workers who can easily be exposed to COVID-19. Following the lead of other countries conducting clinical trials with the live attenuated *Mycobacterium bovis* BCG (BCG) vaccine under a similar concept, a clinical trial with MMR in high-risk populations may provide a “low-risk–high-reward” preventive measure in saving lives during this unprecedented COVID-19 pandemic.

KEYWORDS MMR, clinical trial, inflammation, COVID-19, live attenuated vaccines, myeloid-derived suppressor cells, sepsis, trained innate immunity

There is mounting evidence that the use of live attenuated vaccines commonly administered during childhood also provides beneficial nonspecific effects (NSE), including reduced mortality and hospitalization due to unrelated infections (1, 2). In this Commentary, we outline a rationale to support the use of live attenuated vaccines, such as MMR (measles, mumps, rubella), as a preventive measure against the pathological inflammation and sepsis associated with coronavirus disease 2019 (COVID-19) infection (3). We emphasize this is strictly a preventive measure against the worst inflammatory sequelae of COVID-19 for those exposed/infected and does not represent an antiviral therapy or vaccine against COVID-19 in any manner. It has been proposed that live attenuated vaccines induce nonspecific effects representing “trained innate immunity” by “training” leukocyte precursors in the bone marrow to function more effectively against broader infectious insults (4). In support of this, work from our laboratory demonstrated that vaccination with a live attenuated fungal strain induces trained innate protection against lethal polymicrobial sepsis (Fig. 1) (5–7). The protection is mediated by long-lived myeloid-derived suppressor cells (MDSCs) previously reported to inhibit septic inflammation and mortality in several experimental models (reviewed in reference 7).

The general concept that the trained innate immunity induced by live attenuated vaccines can limit pathological inflammation is novel but not without precedent. At least 6 clinical trials have been initiated in Europe, Australia, and the United States to test vaccination with *Mycobacterium bovis* BCG (live attenuated tuberculosis [TB] vaccine) or

Citation Fidel PL, Jr., Noverr MC. 2020. Could an unrelated live attenuated vaccine serve as a preventive measure to dampen septic inflammation associated with COVID-19 infection? *mBio* 11:e00907-20. <https://doi.org/10.1128/mBio.00907-20>.

Editor Michael S. Gilmore, Harvard Medical School

Copyright © 2020 Fidel and Noverr. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Paul L. Fidel, Jr., pfidel@lsuhsc.edu.

Published




FIG 1 Protection against lethal polymicrobial-community-mediated sepsis by vaccination with an avirulent yeast strain. Mice were vaccinated intraperitoneally with avirulent (live attenuated) *Candida dubliniensis* (Cd) followed by a lethal challenge with *Candida albicans* and *Staphylococcus aureus* (Ca/Sa) intraperitoneally 14 days later. Survival data are shown for 8 independent experiments performed with groups of 10 mice each. The inset shows sepsis scoring during the observation period after lethal challenge. Animals were monitored daily using a modified mouse clinical assessment score for sepsis (M-CASS) scoring system that included fur aspect, posture, activity, and chest and eyelid movement. Animals with a combined daily score of 8+ were humanely euthanized. Data were statistically analyzed using the Mantel-Cox log rank test (survival curves) and two-way analysis of variance (ANOVA) with Bonferroni *post hoc* tests (sepsis scoring) (****, $P < 0.0001$). SEM, standard errors of the means.

placebo in high-risk health care workers to determine whether beneficial trained innate responses against COVID-19 can be elicited (<https://www.sciencemag.org/news/2020/03/can-century-old-tb-vaccine-steel-immune-system-against-new-coronavirus>; <https://www.nytimes.com/2020/05/01/opinion/sunday/coronavirus-vaccine-innate-immunity.html>). In these trials, the proposed trained innate response is one of immune enhancement that could possibly reduce viral levels and/or sequelae associated with COVID-19, similar to what has been reported for other viral infections (2). In contrast, we propose that the trained innate response includes induction of the MDSCs that can inhibit/reduce the severe lung inflammation/sepsis associated with COVID-19. In either regard, on the basis of data from prior BCG trials in infants, the vaccine-induced trained innate cells remain in the circulation for roughly 1 year (8). Hence, if these innate responses are indeed induced in the current clinical trials, recipients should benefit throughout the acute crisis period of the current COVID-19 pandemic until a conventional vaccine is available or antiviral therapies become more accessible. One caveat concerning BCG vaccination is seroconversion, which is the basis for the TB diagnostic test currently used in the United States. Hence, BCG vaccination is not conducted in the United States. We therefore are proposing the use of the live attenuated MMR vaccine, which has also been found to be associated with beneficial NSE in human populations.

According to the Centers for Disease Control (CDC), there are few contraindications against administration to adults of a live attenuated vaccine such as MMR if the recipient is immunocompetent and not pregnant and has not shown previous allergic responses to vaccination (<https://www.cdc.gov/vaccines/vpd/mmr/hcp/recommendations.html>). In fact, MMR vaccination is recommended in high-risk adults (i.e., health care workers) and people born before 1957 who did not receive the vaccine as a child. Adults who had received the MMR vaccine in childhood likely still possess antibody titers against the targeted viruses but not the shorter-lived trained innate leukocytes. Hence, at the very least, the MMR vaccine would provide added protection against measles, mumps, and rubella for older adults. But with the added induction of the trained innate cells, the MMR vaccination could provide protection against the worst sequelae of COVID-19. In direct support of this concept, it was recently reported that the milder symptoms seen

in the 955 sailors on the U.S.S. *Roosevelt* who tested positive for COVID-19 (only one hospitalization) may have been a consequence of the fact that MMR vaccinations are given to all U.S. Navy recruits (<https://www.globenewswire.com/news-release/2020/05/01/2026166/0/en/MMR-Vaccine-May-Reduce-COVID-19-Hospitalization-Rate-According-to-World-Organization.html>). In addition, epidemiological data suggest a correlation between subjects in geographical locations who routinely receive live attenuated measles-rubella vaccines such as the commonly available MMR vaccine, and reduced COVID-19 death rates (https://www.researchgate.net/publication/341354165_MMR_Vaccine_Appears_to_Confer_Strong_Protection_from_COVID-19_Few_Deaths_from_SARS-CoV-2_in_Highly_Vaccinated_Populations).

Looking historically at other viral respiratory epidemics and pandemics of seasonal influenza, severe acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS), one of the more interesting observations is the drastic difference in mortality rates between children and adults (9). Children are highly susceptible to flu; the CDC estimates that since 2010, the number of flu-related hospitalizations among children younger than 5 years of age has ranged from 7,000 to 26,000 in the United States, with approximately 600 deaths in the past 5 years (10). However, very few children were affected during the SARS (2003) or MERS (2012) coronavirus outbreaks (9) and now as well during the COVID-19 outbreak (<https://www.cdc.gov/coronavirus/2019-ncov/specific-groups/children-faq.html>). This is likely due to differences in progression, pathogenesis, and cause of mortality between influenza virus and coronavirus infections. With seasonal flu, mortality is in large part the result of secondary infections, including those by bacterial pneumonia, and of exacerbations of underlying chronic conditions (10). With SARS and MERS, mortality is the result of severe pulmonary inflammation and sepsis induced by the virus resulting in eventual organ failure (3). We hypothesize that one reason that children are protected against viral infections that induce sepsis is their more recent and more frequent exposures to live attenuated vaccines (MMR, rotavirus, smallpox, chickenpox, BCG) that can also induce the trained suppressive MDSCs that limit inflammation and sepsis.

As a response to this hypothesis along with the supportive rationale and considerable observational data supporting the hypothesis, we have proposed a randomized clinical trial to be performed with MMR in New Orleans for high-risk health care workers and first responders. In addition, we have been awarded a Fast Grant (as part of Emergent Ventures at the Mercatus Center, George Mason University) to investigate the level of efficacy of MMR versus that of BCG in a nonhuman primate model of COVID-19 infection. If our hypothesis is correct, MMR (booster) vaccination in adults represents a “low-risk–high-reward” preventive measure to save lives during a critical period of the COVID-19 pandemic.

ACKNOWLEDGMENTS

We claim no conflicts of interest.

Funding related to the animal studies was provided by Foundation of the National Institutes of Health (FNIH), National Institute of Allergy and Infectious Disease, grant R01-AI116025 (Noverr). We also acknowledge clinical support provided by the Louisiana Clinical and Translational Science (LA CaTS) Center, grant U54 GM104940, from the FNIH.

REFERENCES

1. Aaby P, Benn CS. 2019. Developing the concept of beneficial non-specific effect of live vaccines with epidemiological studies. *Clin Microbiol Infect* 25:1459–1467. <https://doi.org/10.1016/j.cmi.2019.08.011>.
2. Moorlag S, Arts RJW, van Crevel R, Netea MG. 2019. Non-specific effects of BCG vaccine on viral infections. *Clin Microbiol Infect* 25:1473–1478. <https://doi.org/10.1016/j.cmi.2019.04.020>.
3. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, J Xu, Tu S, Zhang Y, Chen H, Cao B. 2020. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 395 [https://doi.org/10.1016/S0140-6736\(20\)30566-3](https://doi.org/10.1016/S0140-6736(20)30566-3).
4. Kaufmann E, Sanz J, Dunn JL, Khan N, Mendonça LE, Pacis A, Tzelepis F, Pernet E, Dumaine A, Grenier J-C, Mailhot-Léonard F, Ahmed E, Belle J, Besla R, Mazer B, King IL, Nijnik A, Robbins CS, Barreiro LB, Divangahi M. 2018. BCG educates hematopoietic stem cells to generate protective

- innate immunity against tuberculosis. *Cell* 172:176–190.e19. <https://doi.org/10.1016/j.cell.2017.12.031>.
5. Lilly EA, Ikeh M, Nash EE, Fidel PL, Jr, Noverr MC. 2018. Immune protection against lethal fungal-bacterial intra-abdominal infections. *mBio* 9:e01472-17. <https://doi.org/10.1128/mBio.01472-17>.
 6. Lilly EA, Yano J, Esher SK, Hardie E, Fidel PL, Jr, Noverr MC. 2019. Spectrum of trained innate immunity induced by low-virulence *Candida* species against lethal polymicrobial intra-abdominal infection. *Infect Immun* 87 <https://doi.org/10.1128/IAI.00348-19>.
 7. Esher SK, Fidel PL, Jr, Noverr MC. 2019. *Candida*/staphylococcal polymicrobial intra-abdominal infection: pathogenesis and perspectives for a novel form of trained innate immunity. *J Fungi (Basel)* 5 <https://doi.org/10.3390/jof5020037>.
 8. Biering-Sørensen S, Aaby P, Lund N, Monteiro I, Jensen KJ, Eriksen HB, Scholtz-Buchholzer F, Anne Sofie Pinstrup Jørgensen AS, Rodrigues A, Fisker AB, Stabell Benn C. 2017. Early BCG-Denmark and neonatal mortality among infants weighing <2500 g: a randomized controlled trial. *Clin Infect Dis* 65:1183–1190. <https://doi.org/10.1093/cid/cix525>.
 9. Liu W, Zhang Q, Chen J, Xiang R, Song H, Shu S, Chen L, Liang L, Zhou J, You L, Wu P, Zhang B, Lu Y, Xia L, Huang L, Yang Y, Liu F, Semple MG, Cowling BJ, Lan K, Sun Z, Yu H, Liu Y. 2020. Detection of Covid-19 in children in early January 2020 in Wuhan, China. *N Engl J Med* 382:1370–1371. <https://doi.org/10.1056/NEJMc2003717>.
 10. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team, Da-wood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, Gubareva LV, Xu X, Bridges CB, Uyeki TM. 2009. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. *N Engl J Med* 360:2605–2615. <https://doi.org/10.1056/NEJMoa0903810>.

AUTHOR QUERIES

Below are queries from the copy editor indicating specific areas of concern. Please respond in-line in the main text above, either by marking a change or indicating “ok.”

1

AQau—Please make certain that all authors’ names are spelled correctly, and confirm the given-names and surnames are identified properly by the colors (this is important for how the names are indexed).

■ = Given-Name, ■ = Surname

AQau—An ORCID ID was provided for at least one author during submission. Please click the name associated with the ORCID ID icon (🟡) in the byline to verify that the link is working and that it links to the correct author.

AQabbr—Please check any added introductions of abbreviations and correct them if necessary.

AQfund—The table below includes funding information that you provided on the submission form when you submitted the manuscript. This funding information will not appear in the article, but it will be provided to CrossRef and made publicly available. Please check it carefully for accuracy and mark any necessary corrections. If you would like statements acknowledging financial support to be published in the article itself, please make sure that they appear in the Acknowledgments section. Statements in Acknowledgments will have no bearing on funding data deposited with CrossRef and vice versa.

Funder	Grant(s)	Author(s)	Funder ID
Foundation for the National Institutes of Health (FNIH)	R01AI116025	Mairi C. Noverr	https://doi.org/10.13039/100000009

AQA—Please check the URL

<https://www.globenewswire.com/news-release/MMR-Vaccine-May-Reduce-COVID-19-Hospitalization-Rate-According-to-World-Organization.html>.
